Pharma Mar SA
María Lisa joined PharmaMar June 1st 2022 as Global Commercial Head Oncology. She comes from AstraZeneca as Global Commercial Director, where she had the chance to launch two important indications worldwide in advanced prostate cancer. María Lisa has a broad experience in sales and marketing including, local and Region in Merck Sharp & Dohme, BMS and AbbVie other than AstraZeneca, though her career started in basic research on the cMET oncoprotein.
María Lisa holds a University degree in Biology at Universita' La Sapienza di Roma and an MBA at Luis Business School of Rome. She is Italian-Canadian, has lived and worked in several countries and has learnt to speak 4 languages.
This person is not in any offices
Pharma Mar SA
Pharma Mar SA is a Spain-based company engaged in the bio therapeutic drugs manufacture. The Company focuses on research, development and marketing of bio-active principles, primarily from marine origin, for application in human diseases treatment, including antitumour, antiviral and immunomodulation, as well as tropical diseases areas. It manufactures and sells Yondelis, a synthetically modified antitumor agent, which is derived from sea squirts and is implemented in the treatment of soft tissue sarcomas and relapsed ovarian cancer. Furthermore, the Company's products pipeline comprises drug candidates and agents for cancer treatment, such as Aplidin, PM01183 and PM060184. The Company operates through subsidiaries in Italy, Germany, France, and the United States, among others.